COVID-19 (Coronavirus)

This study is a randomized, double-blind, placebo-controlled, clinical trial designed to evaluate LY3127804 in participants who are hospitalized with pneumonia and presumed or confirmed COVID-19. 

A Study of LY3127804 in Participants With COVID-19

The purpose of this study is to evaluate whether LY3819253 prevents severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease – 2019 (COVID-19) in facility staff and residents in skilled nursing and assisted living facilities with a high risk of SARS-CoV-2 exposure. Participants with a high risk of SARS-CoV-2 exposure will receive LY3819253 or placebo via an injection into a vein. Samples will be taken from the nose. Blood samples will be drawn.

To speak with a study representative, call 718-210-9713.

A Study of LY3819253 (LY-CoV555) to Prevent SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff (BLAZE-2)

The reason for this study is to see if the study drug baricitinib is effective in hospitalized participants with COVID-19.

A Study of Baricitinib (LY3009104) in Participants With COVID-19 (COV-BARRIER)

The purpose of this study is to measure how well LY3819253 and LY3832479 work against the virus that causes COVID-19. LY3819253 and LY3832479 will be given to participants with early symptoms of COVID-19, via an injection into a vein. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 weeks and includes one required visit to the study site, with the remainder of assessments performed in the home or by phone.

COVID-19 (Coronavirus)

Recruiting

|

COVID-19 (Coronavirus)

A Study of LY3819253 (LY-CoV555) to Prevent SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff (BLAZE-2)

Enter your postal code
to see sites near you

View Trial

Recruiting

|

COVID-19 (Coronavirus)

A Study of Baricitinib (LY3009104) in Participants With COVID-19 (COV-BARRIER)

Enter your postal code
to see sites near you

View Trial

Recruiting

|

COVID-19 (Coronavirus)

A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness (BLAZE-1)

Enter your postal code
to see sites near you

View Trial

Not the right fit? Sign up to receive updates on new COVID-19 (Coronavirus) trials.

Active not recruiting

|

COVID-19 (Coronavirus)

A Study of LY3127804 in Participants With COVID-19

Enter your postal code
to see sites near you

View Trial

COVID-19 (Coronavirus)

Recruiting

|

COVID-19 (Coronavirus)

A Study of LY3819253 (LY-CoV555) to Prevent SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff (BLAZE-2)

Enter your postal codeto see sites near you

View Trial

Recruiting

|

COVID-19 (Coronavirus)

A Study of Baricitinib (LY3009104) in Participants With COVID-19 (COV-BARRIER)

Enter your postal codeto see sites near you

View Trial

Recruiting

|

COVID-19 (Coronavirus)

A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness (BLAZE-1)

Enter your postal codeto see sites near you

View Trial

Not the right fit? Sign up to receive updates on new COVID-19 (Coronavirus) trials.

Active not recruiting

|

COVID-19 (Coronavirus)

A Study of LY3127804 in Participants With COVID-19

Enter your postal codeto see sites near you

View Trial

Enter your postal code
to see sites near you

Enter your postal code
to see sites near you

Enter your postal code
to see sites near you

Enter your postal code
to see sites near you